RedHill Biopharma Reports Top-Line Data from Opaganib Phase 2/3 Study in Severe COVID-19 Patients

Company contact: Adi Frish Chief Corporate & Business Development Officer RedHill Biopharma +972-54-6543-112 |
Media contacts: U.S.:?Bryan Gibbs, Finn Partners +1 212 529 2236 UK:?Amber Fennell, Consilium +44 (0) 7739 658 783 ? |
[2]?Xia C. et al. Transient inhibition of sphingosine kinases confers protection to influenza A virus infected mice. Antiviral Res. 2018 Oct; 158:171-177. Ebenezer DL et al. Pseudomonas aeruginosa?stimulates nuclear sphingosine-1-phosphate generation and epigenetic regulation of lung inflammatory injury. Thorax. 2019 Jun;74(6):579-591.
[3]?Full prescribing information for Movantik??(naloxegol) is available at:?www.Movantik.com.??
[4]?Full prescribing information for Talicia??(omeprazole magnesium, amoxicillin and rifabutin) is available at:?www.Talicia.com.??????
[5]?Full prescribing information for Aemcolo??(rifamycin) is available at:?www.Aemcolo.com. Logo -?https://mma.prnewswire.com/media/1334141/RedHill_Biopharma_Logo.jpg SOURCE RedHill Biopharma Ltd.